565 related articles for article (PubMed ID: 25941226)
21. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
22.
Yu X; Gao X; Li C; Luo J; Wen S; Zhang T; Ma Y; Dong L; Wang F; Huang H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138571
[TBL] [Abstract][Full Text] [Related]
23. Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for
Sivaramakrishnan G; Subramanyam B; Kumar MP; Golla R; Tripathy SP; Mondal R
Int J Mycobacteriol; 2019; 8(4):329-332. PubMed ID: 31793501
[TBL] [Abstract][Full Text] [Related]
24. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
[TBL] [Abstract][Full Text] [Related]
25. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
26. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
27. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
28. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
[TBL] [Abstract][Full Text] [Related]
30. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
[TBL] [Abstract][Full Text] [Related]
31. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
[TBL] [Abstract][Full Text] [Related]
32. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
33. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
[No Abstract] [Full Text] [Related]
34. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
37. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lessem E; Cox V; Furin J
Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
[No Abstract] [Full Text] [Related]
38. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
[TBL] [Abstract][Full Text] [Related]
39. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
40. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of
Negi A; Perveen S; Gupta R; Singh PP; Sharma R
J Med Chem; 2024 Feb; 67(4):2264-2286. PubMed ID: 38351709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
